Synspira Therapeutics names new CEO
Photo | Google
Synspira Therapeutics is headquartered in this Framingham facility.
Framingham clinical-stage biopharma Synspira Therapeutics has named a new CEO with experience in leading biotech companies from startup stage to market.
Robert Gallotto will take over at the helm of the firm, which is developing drugs for patients with cystic fibrosis and other rare progressive pulmonary diseases.
Gallotto takes over for Shenda Baker, who served as interim CEO.
Gallotto was the co-founder of Alcresta Therapeutics and Allena Pharmaceuticals, the former of which successfully launched its first medical device, RELiZORB, in 2016.
Gallotto served as chief business officer of Alnara Pharmaceuticals, which was acquired by Eli Lilly and Co. in 2010 for $380 million.
His 30-year career in biotech includes a variety of roles in strategic planning, commercial development, marketing and business development at Biogen, Ares-Serono, Sage BioPharma and the Upjohn Co.
In a statement, Gallotto said the company’s lead product, SNSP113, has the potential to be a new class of therapies to target the underlying conditions leading to progressive pulmonary diseases.
“I look forward to working with the Synspira team and investors, as well as our partners and the patient community, in order to deliver on the promise of SNSP113 -- to change the course of life-threatening progressive pulmonary diseases,” he said.
WBJ Web Partners
Most Recent
Most Recent
0 Comments